Cyclopropyl amide derivatives targeting the histamine H3 receptor

Details for Australian Patent Application No. 2010216454 (hide)

Owner AstraZeneca AB

Inventors Griffin, Andrew

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2010216454

PCT Pub. Number WO2010/096011

Priority 61/154,067 20.02.09 US

Filing date 19 February 2010

Wipo publication date 26 August 2010

International Classifications

C07D 241/04 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

25 August 2011 PCT application entered the National Phase

  PCT publication WO2010/096011 Priority application(s): WO2010/096011

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010216472-Mixture of inorganic compounds, preparations containing the mixture and use of the mixture

2010216430-Resin infusion potting